Semaglutide Eligibility Across All Current Indications for US Adults
Authors:
Top Cited Papers
Open Access
- 1 January 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 10 (1) , 96
Abstract
Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion.1,2 Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.Keywords
This publication has 5 references indexed in Scilit:
- Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk EquationsJAMA, 2024
- Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If UnaffordableJAMA, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsDiabetes & Metabolism, 2019